Docencia en sistemas de acceso á información: detección de plaxios, emprego de tecnoloxías avanzadas para desenvolvemento software e achegamento da experiencia na industria á aula

[Resumo] Este artigo presenta as actividades desenvolvidas polo grupo de innovación educativa en Sistemas de Acceso á Información durante o curso 2017/2018. Este grupo, con docencia na Facultade de Informática da Universidade da Coruña, realizou accións en tres liñas de actuación diferentes. A primeira delas, dirixida á mellora da calidade nos métodos de avaliación, consiste no emprego dun protocolo para a detección de plaxios en prácticas de programación. A segunda actividade pretende mellorar a empregabilidade do alumnado e consiste en utilizar unha metodoloxía de aprendizaxe baseada en proxectos xunto cunha serie de ferramentas avanzadas para desenvolvemento software, permitindo recrear a actividade que deberán levar a cabo cando se incorporen ao mundo laboral. Por último, e de cara a aumentar o coñecemento das alternativas profesionais do alumnado, organizáronse unha serie de seminarios e charlas impartidas por profesionais dunha empresa internacional, unha empresa local multidisciplinar e un investigador da contorna académica. A experiencia obtida das diferentes actividades foi satisfactoria e enriquecedora tanto para o alumnado como para o profesorado, que xa baralla melloras de cara aos vindeiros cursos académicos.[Abstract] This paper presents the activities performed by the educative innovation group in Information Access Systems during the academic year 2017/2018. This group, with teaching at the Faculty of Informatics of the University of A Coruña, carried out actions addressing three different topics. The first action was designed to improve the quality of the evaluation methods, and consisted in following a protocol for detecting plagiarism in programming exercises. The second activity aimed to improve the employability of the students and consisted in using a methodology based on project-based learning along with a series of advanced tools for software development, which recreated the activity that the students will carry out when they obtain their first job. Lastly, heading towards a better knowledge about the available professional alternatives, a series of seminars and talks were organized, which were performed by professionals from an international company, a local interdisciplinary company, and a researcher from an academic institution. The experience obtained from the different activities was satisfactory for both students and teachers, who are already considering improvements for the next academic year

Statins in prevention of Alzheimer’s disease

Traballo Fin de Grao en Medicina. Curso 2020-2021Introducción: La enfermedad de Alzheimer (EA) tiene una carga epidemiológica y funcional muy elevada, cursa clínicamente como una degeneración cognitiva insidiosa y progresiva, y no se dispone en la actualidad de tratamiento específico prometedor alguno. Diversos diseños observacionales han demostrado una relación entre la hipercolesterolemia y un incremento de riesgo de EA, sugiriendo una posible asociación entre la terapia estatínica y una incidencia disminuida de este tipo de demencia. Objetivo: Evaluar la efectividad de las estatinas como terapia de prevención primaria de enfermedad de Alzheimer, y estudiar si la eficacia de las mismas para este fin depende del nivel de colesterol basal o genotipo de apoE, entre otros. Método y diseño de estudio: Se llevó a cabo una revisión sistemática cualitativa de la bibliografía disponible en la base de datos MEDLINE, empleando terminología MeSH y filtrando según criterios de inclusión, para finalmente incluir diseños experimentales a partir del 2002. Se revisaron ocho ensayos clínicos aleatorizados, doble ciego y controlados con placebo, en los que se estudió el efecto de la intervención con estatinas en poblaciones sin patología degenerativa cognitiva pero en riesgo de desarrollarla. Resultados: Los estudios revisados difirieron en cuanto a la intervención empleada, el tamaño muestral y el periodo de seguimiento. Los parámetros evaluados como resultado primario fueron el nuevo diagnóstico de EA o deterioro cognitivo leve, o, en su mayoría, parámetros indirectos que así lo pudieran sugerir. A pesar de que en tres de los trabajos sí se establecieron diferencias significativas entre grupos de tratamiento (p<0.05), el resto de estudios, y los dos con mayor peso, no mostraron una reducción en la incidencia de Alzheimer en los sujetos tratados con estatina en comparación a los aleatorizados a placebo. Discusión y conclusiones: La toma de estatinas en edades avanzadas de la vida de sujetos en riesgo de patología vascular no tiene efecto en la incidencia de demencia o declive cognitivo, con lo que el uso de estos fármacos para este fin es, a dia de hoy, infundado. De los estudios que sí encontraron diferencias significativas, no se pudo inferir, por no evaluar directamente el diagnóstico per se de demencia, que la intervención supusiera un beneficio en la incidencia de la enfermedad. Nuevos estudios prospectivos ampliando el campo de acción y características poblacionales se hacen necesariosIntrodución: A enfermidade de Alzheimer (EA) ten unha carga epidemiolóxica e funcional moi elevada, cursa clinicamente como unha dexeneración cognitiva insidiosa e progresiva, e non se dispón na actualidade de tratamento específico prometedor algún. Diversos deseños observacionais demostraron unha relación entre a hipercolesterolemia e un incremento de risco de EA, suxerindo unha posible asociación entre a terapia estatínica e unha incidencia diminuída deste tipo de demencia. Obxectivo: Avaliar a efectividade das estatinas como terapia de prevención primaria de enfermidade de Alzheimer, e estudar se a eficacia das mesmas para este fin depende do nivel de colesterol basal ou xenotipo de apoE, entre outros. Método e deseño de estudo: Levouse a cabo unha revisión sistemática cualitativa da bibliografía dispoñible na base de datos MEDLINE, empregando terminoloxía MeSH e filtrando segundo criterios de inclusión, para finalmente incluír deseños experimentais a partir do 2002. Revisáronse oito ensaios clínicos aleatorizados, dobre cego e controlados con placebo, nos que se estudou o efecto da intervención con estatinas en poboacións sen patoloxía dexenerativa cognitiva pero en risco de desenvolvela. Resultados: Os estudos revisados diferiron en canto á intervención empregada, o tamaño muestral e o período de seguimento. Os parámetros avaliados como resultado primario foron o novo diagnóstico de EA ou deterioración cognitiva leve, ou, na súa maioría, parámetros indirectos que así o puidesen suxerir. A pesar de que en tres dos traballos si se estableceron diferenzas significativas entre grupos de tratamento ( p<0.05), o resto de estudos, e os dous con maior peso, non mostraron unha redución na incidencia de Alzheimer nos suxeitos tratados con estatina en comparación aos aleatorizados a placebo. Discusión e conclusións: A toma de estatinas en idades avanzadas da vida de suxeitos en risco de patoloxía vascular non ten efecto na incidencia de demencia ou declive cognitivo, co que o uso destes fármacos para este fin é, a día de hoxe, infundado. Dos estudos que si atoparon diferenzas significativas, non se puido inferir, por non avaliar directamente o diagnóstico per se de demencia, que a intervención supuxese un beneficio na incidencia da enfermidade. Novos estudos prospectivos ampliando o campo de acción e características poboacionais fanse necesariosIntroduction: Alzheimer's disease (AD) has a very high epidemiological and functional burden, presents clinically as an insidious and progressive cognitive degeneration, and no promising specific treatment is currently available. Several observational designs have demonstrated a relationship between hypercholesterolemia and an increased risk of AD, suggesting a possible association between statin therapy and a decreased incidence of this type of dementia. Objective: To evaluate the effectiveness of statins as primary prevention therapy for Alzheimer's disease, and to study whether the efficacy of statins for this purpose depends on baseline cholesterol level or apoE genotype, among others. Study method and design: A qualitative systematic review of the literature available in the MEDLINE database was carried out, using MeSH terminology and filtering according to inclusion criteria, to finally include experimental designs from 2002 onwards. Eight randomized, double-blind, placebo-controlled clinical trials were reviewed, in which the effect of intervention with statins was studied in populations without cognitive degenerative pathology but at risk of developing it. Results: The studies reviewed differed in terms of the intervention used, sample size and follow-up period. The parameters evaluated as primary outcome were the new diagnosis of AD or mild cognitive impairment, or, for the most part, indirect parameters that could suggest it. Although three of the studies did establish significant differences between treatment groups (p<0.05), the remaining studies, and the two with the greatest weight, did not show a reduction in the incidence of Alzheimer's disease in subjects treated with statin compared to those randomized to placebo. Discussion and conclusions: The use of statins at older ages in subjects at risk of vascular pathology has no effect on the incidence of dementia or cognitive decline, so that the use of these drugs for this purpose is, to date, unfounded. Of the studies that did find significant differences, it could not be inferred, because they did not directly assess the diagnosis of dementia per se, that the intervention would have a benefit on the incidence of the disease. New prospective studies broadening the field of action and population characteristics are neede

Workshop to review and progress the reported lists of eu msfd descriptor 3 ( (WKD3LISTS)

info:eu-repo/semantics/publishedVersio

Diagnostico del Impacto del Palangre de Fondo en los Hábitats Bentónicos en los LICs de la RN20000

En prens

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Strong Interaction Physics at the Luminosity Frontier with 22 GeV Electrons at Jefferson Lab

This document presents the initial scientific case for upgrading the Continuous Electron Beam Accelerator Facility (CEBAF) at Jefferson Lab (JLab) to 22 GeV. It is the result of a community effort, incorporating insights from a series of workshops conducted between March 2022 and April 2023. With a track record of over 25 years in delivering the world's most intense and precise multi-GeV electron beams, CEBAF's potential for a higher energy upgrade presents a unique opportunity for an innovative nuclear physics program, which seamlessly integrates a rich historical background with a promising future. The proposed physics program encompass a diverse range of investigations centered around the nonperturbative dynamics inherent in hadron structure and the exploration of strongly interacting systems. It builds upon the exceptional capabilities of CEBAF in high-luminosity operations, the availability of existing or planned Hall equipment, and recent advancements in accelerator technology. The proposed program cover various scientific topics, including Hadron Spectroscopy, Partonic Structure and Spin, Hadronization and Transverse Momentum, Spatial Structure, Mechanical Properties, Form Factors and Emergent Hadron Mass, Hadron-Quark Transition, and Nuclear Dynamics at Extreme Conditions, as well as QCD Confinement and Fundamental Symmetries. Each topic highlights the key measurements achievable at a 22 GeV CEBAF accelerator. Furthermore, this document outlines the significant physics outcomes and unique aspects of these programs that distinguish them from other existing or planned facilities. In summary, this document provides an exciting rationale for the energy upgrade of CEBAF to 22 GeV, outlining the transformative scientific potential that lies within reach, and the remarkable opportunities it offers for advancing our understanding of hadron physics and related fundamental phenomena.Comment: Updates to the list of authors; Preprint number changed from theory to experiment; Updates to sections 4 and 6, including additional figure

[Montreal 1976] [Material gráfico]

Contiene fotografías pertenecientes al archivo fotográfico del diario "Región", publicadas entre 1974 y 1976, aunque la mayoría en 1976Todas las fotografías firmadas por Foto E. Gar (Oviedo), Cifra Gráfica, y EF

Measurement of the properties of the Ξb∗0\Xi_b^{*0} baryon

See paper for full list of authors - 18 pages, 5 figures. All figures and tables, along with any supplementary material and additional information, are available at this https URLInternational audienceWe perform a search for near-threshold Ξ0b resonances decaying to Ξ−bπ+ in a sample of proton-proton collision data corresponding to an integrated luminosity of 3 fb−1 collected by the LHCb experiment. We observe one resonant state, with the following properties:m(Ξ∗0b)−m(Ξ−b)−m(π+)=15.727±0.068(stat)±0.023(syst)MeV/c2,Γ(Ξ∗0b)=0.90±0.16(stat)±0.08(syst)MeV.This confirms the previous observation by the CMS collaboration. The state is consistent with the JP=3/2+ Ξ∗0b resonance expected in the quark model. This is the most precise determination of the mass and the first measurement of the natural width of this state. We have also measured the ratioσ(pp→Ξ∗0bX)B(Ξ∗0b→Ξ−bπ+)σ(pp→Ξ−bX)=0.27±0.03(stat)±0.01(syst)